ECSP23088759A - Anticuerpos anti-clec12a y usos de los mismos - Google Patents

Anticuerpos anti-clec12a y usos de los mismos

Info

Publication number
ECSP23088759A
ECSP23088759A ECSENADI202388759A ECDI202388759A ECSP23088759A EC SP23088759 A ECSP23088759 A EC SP23088759A EC SENADI202388759 A ECSENADI202388759 A EC SENADI202388759A EC DI202388759 A ECDI202388759 A EC DI202388759A EC SP23088759 A ECSP23088759 A EC SP23088759A
Authority
EC
Ecuador
Prior art keywords
antibodies
fragments
fusion proteins
clec12a
leukemia
Prior art date
Application number
ECSENADI202388759A
Other languages
English (en)
Spanish (es)
Inventor
Tomoki Yoshihara
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of ECSP23088759A publication Critical patent/ECSP23088759A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ECSENADI202388759A 2021-04-26 2023-11-23 Anticuerpos anti-clec12a y usos de los mismos ECSP23088759A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163179755P 2021-04-26 2021-04-26

Publications (1)

Publication Number Publication Date
ECSP23088759A true ECSP23088759A (es) 2024-01-31

Family

ID=81648460

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202388759A ECSP23088759A (es) 2021-04-26 2023-11-23 Anticuerpos anti-clec12a y usos de los mismos

Country Status (18)

Country Link
US (1) US12600784B2 (cg-RX-API-DMAC7.html)
EP (1) EP4330284A2 (cg-RX-API-DMAC7.html)
JP (1) JP2024516645A (cg-RX-API-DMAC7.html)
KR (1) KR20240004286A (cg-RX-API-DMAC7.html)
CN (1) CN117545774A (cg-RX-API-DMAC7.html)
AR (1) AR125451A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022266584A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023020365A2 (cg-RX-API-DMAC7.html)
CA (1) CA3216770A1 (cg-RX-API-DMAC7.html)
CL (2) CL2023003177A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023014316A2 (cg-RX-API-DMAC7.html)
EC (1) ECSP23088759A (cg-RX-API-DMAC7.html)
IL (1) IL307939A (cg-RX-API-DMAC7.html)
MX (1) MX2023011710A (cg-RX-API-DMAC7.html)
PE (1) PE20241789A1 (cg-RX-API-DMAC7.html)
PH (1) PH12023552669A1 (cg-RX-API-DMAC7.html)
TW (1) TW202309084A (cg-RX-API-DMAC7.html)
WO (1) WO2022232044A2 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022266583A1 (en) 2021-04-26 2023-10-19 Millennium Pharmaceuticals, Inc. Anti-adgre2 antibodies and uses thereof
JP2024514974A (ja) 2021-04-26 2024-04-03 メモリアル スローン-ケタリング キャンサー センター Adgre2及び/またはclec12aを標的とするキメラ受容体及びその使用
WO2024254778A1 (en) * 2023-06-14 2024-12-19 Zhejiang Shimai Pharmaceutical Co., Ltd. Antibodies against cll1 and uses thereof

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3681787D1 (de) 1985-07-05 1991-11-07 Whitehead Biomedical Inst Expression von fremdem genetischem material in epithelzellen.
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
HK1008049A1 (en) 1987-09-11 1999-04-30 Whitehead Institute For Biomedical Research Transduced fibroblasts and use therefor
ATE110108T1 (de) 1987-12-11 1994-09-15 Whitehead Biomedical Inst Genetische modifizierung von endothelialen zellen.
DE68927996T2 (de) 1988-02-05 1997-12-04 Hughes Howard Med Inst Modifizierte hepatozyten und deren anwendung
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
DE69123981T3 (de) 1990-10-31 2006-06-14 Cell Genesys Inc Nützliche retrovirale vektoren für die gentherapie
JPH07503124A (ja) 1991-06-14 1995-04-06 ゾーマ・コーポレーション 微生物によって生産される抗体断片とそれらの複合体
SE9201984D0 (sv) 1992-06-29 1992-06-29 Pharmacia Biosensor Ab Improvement in optical assays
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US5308341A (en) 1993-09-28 1994-05-03 Becton, Dickinson And Company Method of testing the dose accuracy of a medication delivery device
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5773019A (en) 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US6146361A (en) 1996-09-26 2000-11-14 Becton Dickinson And Company Medication delivery pen having a 31 gauge needle
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
JP3876002B2 (ja) 1997-04-14 2007-01-31 ミクロメート・アクチエンゲゼルシャフト 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用
WO1998047531A2 (en) 1997-04-21 1998-10-29 Arch Development Corporation Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy
US6302855B1 (en) 1998-05-20 2001-10-16 Novo Nordisk A/S Medical apparatus for use by a patient for medical self treatment of diabetes
US6192891B1 (en) 1999-04-26 2001-02-27 Becton Dickinson And Company Integrated system including medication delivery pen, blood monitoring device, and lancer
US6277099B1 (en) 1999-08-06 2001-08-21 Becton, Dickinson And Company Medication delivery pen
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
ATE547080T1 (de) 2000-08-30 2012-03-15 Univ Johns Hopkins Vorrichtungen zur intraokularen arzneimittelabgabe
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
JP4383168B2 (ja) 2001-09-12 2009-12-16 ベクトン・ディキンソン・アンド・カンパニー マイクロ針投与デバイスおよび薬物投与デバイス
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
US20040102469A1 (en) 2002-09-13 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Method for reducing the mortality rate
GB0222023D0 (en) 2002-09-21 2002-10-30 Aventis Pharma Ltd Inhaler
FR2849436B1 (fr) 2002-12-27 2007-01-05 Patrick Frayssinet Particules et ceramiques de phosphates de calcium pour transfection in vivo et in vitro
WO2004073551A2 (en) 2003-02-18 2004-09-02 Massachusetts Eye And Ear Infirmary Transscleral drug delivery device and related methods
WO2006130834A2 (en) 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
CA2693771A1 (en) 2007-07-13 2009-01-22 Abbott Biotechnology Ltd. Methods and compositions for pulmonary administration of a tnf.alpha. inhibitor
NZ602220A (en) 2010-03-11 2014-10-31 Rinat Neuroscience Corp Antibodies with ph dependent antigen binding
EP2622074B1 (en) 2010-09-30 2014-11-12 Board Of Trustees Of Northern Illinois University Library-based methods and compositions for introducing molecular switch functionality into protein affinity reagents
US9163090B2 (en) * 2012-05-07 2015-10-20 Cellerant Therapeutics, Inc. Antibodies specific for CLL-1
BR112015006824A2 (pt) 2012-09-27 2017-07-04 Merus B V anticorpo igg biespecífico, método para produzir um anticorpo igg biespecífico, anticorpo, composição farmacêutica e uso de um anticorpo igg biespecífico
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
MA40579A (fr) * 2014-09-12 2016-03-17 Genentech Inc Anticorps anti-cll-1 et immunoconjugués
TW201718647A (zh) * 2015-06-16 2017-06-01 建南德克公司 抗-cll-1抗體及使用方法
MX2020002880A (es) 2017-09-14 2020-10-01 Dragonfly Therapeutics Inc Proteínas que se unen a nkg2d, cd16 y a la molécula 1 similar a lectina de tipo c (cll-1).
WO2019108065A1 (en) * 2017-12-01 2019-06-06 Merus N.V. Use of bispecific antibody and il-15 for combination therapy
US11951129B2 (en) * 2018-01-09 2024-04-09 H. Lee Moffitt Cancer Center And Research Institute, Inc. Compositions and methods for targeting CLEC12A-expressing cancers
AU2019414968A1 (en) * 2018-12-27 2021-08-12 Gigagen, Inc. Anti-PD-1 binding proteins and methods of use thereof
KR20220004751A (ko) * 2019-05-04 2022-01-11 인히브릭스, 인크. CLEC12a 결합 폴리펩타이드 및 이의 용도
AU2021268340A1 (en) 2020-05-06 2022-12-08 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and CLEC12A
AU2022266583A1 (en) 2021-04-26 2023-10-19 Millennium Pharmaceuticals, Inc. Anti-adgre2 antibodies and uses thereof
JP2024514974A (ja) * 2021-04-26 2024-04-03 メモリアル スローン-ケタリング キャンサー センター Adgre2及び/またはclec12aを標的とするキメラ受容体及びその使用

Also Published As

Publication number Publication date
CL2025002212A1 (es) 2025-10-24
US12600784B2 (en) 2026-04-14
EP4330284A2 (en) 2024-03-06
AU2022266584A9 (en) 2023-10-26
IL307939A (en) 2023-12-01
PE20241789A1 (es) 2024-09-06
CO2023014316A2 (es) 2023-11-20
CN117545774A (zh) 2024-02-09
WO2022232044A2 (en) 2022-11-03
WO2022232044A3 (en) 2022-12-08
CA3216770A1 (en) 2022-11-03
MX2023011710A (es) 2023-10-12
BR112023020365A2 (pt) 2023-11-21
AR125451A1 (es) 2023-07-19
JP2024516645A (ja) 2024-04-16
KR20240004286A (ko) 2024-01-11
TW202309084A (zh) 2023-03-01
PH12023552669A1 (en) 2024-02-19
US20230111279A1 (en) 2023-04-13
AU2022266584A1 (en) 2023-10-12
CL2023003177A1 (es) 2024-05-24

Similar Documents

Publication Publication Date Title
ECSP23088752A (es) Anticuerpos anti-adgre2 y usos de los mismos
CO2023014316A2 (es) Anticuerpos anti-clec12a y usos de los mismos
UY37591A (es) Conjugados de fármaco anticuerpo
CL2020003285A1 (es) Anticuerpos anti-psma x anti-cd28 biespecificos y usos de estos.
DOP2017000047A (es) Anticuerpos anti-lag3 y fragmentos de unión a antígeno
CO2020000214A2 (es) Anticuerpos agonistas que se unen a cd137 humano y sus usos
CL2024003715A1 (es) Proteína de unión multiespecífica que se une a nkg2d, cd33 y cd16; composición; y uso.
CL2019003520A1 (es) Anticuerpos que se unen específicamente a pd-1 y procedimientos de uso.
PE20211860A1 (es) Proteinas de union multiespecificas que se unen a bcma, nkg2d y cd16 y metodos de uso
MX2019014465A (es) Anticuerpos especificos para flt3 y sus usos.
PE20220142A1 (es) Anticuerpos de cadena pesada que se unen al psma
UY37698A (es) Proteínas de unión a antígenos trem2 y usos de estas
AR116718A1 (es) Proteínas de unión triespecíficas anti-cd38, anti-cd28 y anti-cd3 y métodos de uso para tratar infección vírica
MX2021007768A (es) Anticuerpos anti-ctla4 y metodos de uso de los mismos.
MX374810B (es) Anticuerpos 4-1bb anti-humano y usos de los mismos
MX2016012094A (es) Composiciones de anticuerpos para tratamiento tumoral.
UY36942A (es) Proteínas de unión a antígeno que activan el receptor de leptina
CO2020009402A2 (es) Proteínas de fusión fc il-22 y métodos de uso
UY36539A (es) Proteínas de unión a icos
PE20190510A1 (es) Anticuerpos anti-pd-l1 y usos de los mismos
MX2019011961A (es) Terapias combinadas dirigidas a proteina 1 de muerte celular programada (pd-1), proteina 3 de dominio de mucina y dominio inmunoglobulina de los linfocitos t (tim-3), y gen de activacion de linfocitos 3 (lag-3).
CL2023001492A1 (es) Anticuerpos anti-ly6g6d y métodos de uso.
ECSP18096095A (es) Anticuerpos a la alfa-sinucleína y usos de los mismos
EA202092302A1 (ru) Антитела к trem-1 и их применения
BR112022011824A2 (pt) Anticorpos de cadeia pesada que se ligam a cd38